keyword
https://read.qxmd.com/read/38523019/prognostication-in-chronic-lymphocytic-leukemia
#21
JOURNAL ARTICLE
Riccardo Moia, Gianluca Gaidano
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in Western countries. CLL is a highly heterogeneous disease: some patients may never require therapy and others relapse several times after different therapeutic strategies. Therefore, in CLL, prognostic markers are essential to capture high-risk patients for different clinical endpoints including early treatment requirement, early progression after BTK or BCL2 inhibitors and Richter transformation. In early stage CLL, different biological and clinical biomarkers have been identified to predict time to treatment requirement that could be used to identify the most appropriate population for early intervention clinical trial...
March 1, 2024: Seminars in Hematology
https://read.qxmd.com/read/38522578/the-role-of-molecular-or-cytogenetic-response-as-a-favorable-prognostic-factor-before-hematopoietic-stem-cell-transplantation-for-chronic-myeloid-leukemia
#22
JOURNAL ARTICLE
Giuliana Rosendo de Oliveira Medeiros, Vaneuza Araújo Moreira Funke, Alberto Cardoso Martins Lima, Ana Lúcia Vieira Mion, Isabela Menezes, Daniela Carinhanha Setubal, Caroline Bonamin Dos Santos Sola, Gláucia Tagliari, Rafael Marchesini, Samir Kanaan Nabhan, Ricardo Pasquini
Tyrosine kinase inhibitors (TKIs) have revolutionized therapy for patients with chronic myeloid leukemia (CML) over the last two decades. However, some patients still do not achieve an adequate response to these drugs, and hematopoietic stem cell transplantation (HSCT) is indicated in this scenario. We present the results of a 20-year follow-up study of 70 patients who underwent transplantation after TKI failure. The primary objective of the study was to evaluate overall survival (OS) and the secondary objective was to evaluate the outcomes of relapse-free survival (RFS), GVHD-free, relapse-free survival (GFRS) and the incidences of relapse (RI), non-relapse mortality (NRM), acute and chronic GVHD...
March 22, 2024: Transplantation and cellular therapy
https://read.qxmd.com/read/38520901/comparing-the-impact-of-acupressure-and-reflexology-on-fatigue-in-chronic-lymphocytic-leukemia-patients-a-randomized-controlled-trial-with-three-arms
#23
JOURNAL ARTICLE
Naser Parizad, Amireh Hassanpour, Rasoul Goli, Hamidreza Khalkhali, Aysan Nozad
PURPOSE: This study aimed to evaluate the effects of acupressure and reflexology on fatigue in chronic lymphocytic leukemia patients. METHOD: In this randomized controlled trial with three arms and a pretest-posttest design, 102 CLL patients were randomly allocated to acupressure (n = 34), reflexology (n = 34), or control (n = 34) groups. Pre-intervention assessments were conducted using a demographic questionnaire and a fatigue scale for cancer patients...
March 19, 2024: European Journal of Oncology Nursing: the Official Journal of European Oncology Nursing Society
https://read.qxmd.com/read/38517548/secondary-solid-malignancies-and-precancerous-lesions-after-allogeneic-hematopoietic-stem-cell-transplantation-using-non-total-body-irradiation-based-conditioning-in-acute-myeloid-leukemia
#24
JOURNAL ARTICLE
Gruber Isabella, Appel Katharina, Edinger Matthias, Koelbl Oliver, Wolff Daniel
INTRODUCTION: Long-term survivors have an increased risk of developing secondary solid malignancies (SSMs) after allogeneic-hematopoietic stem cell transplantation (allo-HSCT) with graft-versus-host disease (GVHD) potentially modulating these risks. METHODS: This retrospective study analyzed the cumulative incidences of SSMs after chemotherapy-based conditioning for allo-HSCT patients with acute myeloid leukemia (n = 266) transplanted at the University Hospital Regensburg between 1999 and 2016...
March 22, 2024: Journal of Cancer Research and Clinical Oncology
https://read.qxmd.com/read/38517058/computer-aided-drug-discovery-of-c-abl-kinase-inhibitors-from-plant-compounds-against-chronic-myeloid-leukemia
#25
JOURNAL ARTICLE
Mohammed M Alshehri, Neeraj Kumar, Najwa Ahmad Kuthi, Zainab Olaide, Mohammed Kanan Alshammari, Ridwan Opeyemi Bello, Mohammed Khalid Alghazwni, Ahmed Mughram Alshehri, Omaymah Mohammed Alshlali, Zainab Ashimiyu-Abdusalam, Haruna Isiyaku Umar
Chronic myeloid leukemia (CML) is a hematological malignancy characterized by the neoplastic transformation of hematopoietic stem cells, driven by the Philadelphia (Ph) chromosome resulting from a translocation between chromosomes 9 and 22. This Ph chromosome harbors the breakpoint cluster region (BCR) and the Abelson (ABL) oncogene (BCR-ABL1) which have a constitutive tyrosine kinase activity. However, the tyrosine kinase activity of BCR-ABL1 have been identified as a key player in CML initiation and maintenance through c-Abl kinase...
March 22, 2024: Journal of Biomolecular Structure & Dynamics
https://read.qxmd.com/read/38516702/metabolic-and-toxicological-considerations-of-bruton-s-tyrosine-kinase-inhibitors-for-the-treatment-of-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma
#26
REVIEW
Anna Wolska-Washer, Paweł Robak, Magdalena Witkowska, Tadeusz Robak
INTRODUCTION: Bruton tyrosine kinase inhibitors (BTKi) have been used for the management of human diseases since the approval of the first-in class agent, ibrutinib, by the Food and Drug Administration in 2013 for the treatment of patients with mantle cell lymphoma (MCL). Ibrutinib is a covalent inhibitor along with second-class BTKis: acalabrutinib and zanubrutinib. These well-tolerated agents have transformed the treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)...
March 22, 2024: Expert Opinion on Drug Metabolism & Toxicology
https://read.qxmd.com/read/38516352/reintegration-into-school-kindergarten-and-work-in-families-of-childhood-cancer-survivors-after-a-family-oriented-rehabilitation-program
#27
JOURNAL ARTICLE
Laura Inhestern, Mona L Nasse, Konstantin A Krauth, Daniela Kandels, Stefan Rutkowski, Gabriele Escherich, Corinna Bergelt
OBJECTIVE: To describe the situation of childhood cancer survivors and their parents before and one year after a family-oriented rehabilitation program (FOR) and to identify factors influencing reintegration. METHODS: We included parents of children diagnosed with leukemia or central nervous system tumor. We assessed parental functioning using the functioning subscale of the Ulm Quality of Life Inventory for Parents (ULQIE) and children's school/kindergarten related quality of life (parental assessment, subscale KINDL-R)...
2024: Frontiers in Pediatrics
https://read.qxmd.com/read/38513148/predictive-value-of-early-molecular-response-to-tyrosine-kinase-inhibitors-in-pediatric-patients-with-chronic-myeloid-leukemia
#28
JOURNAL ARTICLE
Aya M Abdallah, Hanafy Hafez, Youssef Madney, Sonia Ahmed, Dina Yassin, Sherine Salem, Rodina Yousry, Hisham Abdel-Azim, Leslie Lehmann, Alaa Elhaddad
No abstract text is available yet for this article.
March 21, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38513082/therapy-related-chronic-myelomonocytic-leukemia-does-not-have-the-high-risk-features-of-a-therapy-related-neoplasm
#29
JOURNAL ARTICLE
Alex Bataller, Georgina Gener-Ricos, Emmanuel Almanza, Kelly Sharon Chien, Samuel Urrutia, Alexandre Bazinet, Juan Jose Rodriguez-Sevilla, Danielle Hammond, Koji Sasaki, Koichi Takahashi, Courtney D DiNardo, Farhad Ravandi, Gautam Borthakur, Tapan M Kadia, Rashmi Kanagal-Shamanna, Hagop M Kantarjian, Guillermo Garcia-Manero, Guillermo Montalban-Bravo
Therapy-related myeloid neoplasms (t-MNs) arise after exposure to cytotoxic therapies and are associated with high-risk genetic features and poor outcomes. We analyzed a cohort of patients with therapy-related chronic myelomonocytic leukemia (tCMML; n = 71) and compared its features to that of de novo CMML (dnCMML; n = 461). Median time from cytotoxic therapy to tCMML diagnosis was 6.5 years. Compared with dnCMML, chromosome 7 abnormalities (4% vs. 13%; P = .005), but not complex karyotype (3% vs. 7%; P = ...
March 21, 2024: Blood Advances
https://read.qxmd.com/read/38512136/antigen-independent-autonomous-b-cell-receptor-signaling-drives-activated-b-cell-dlbcl
#30
JOURNAL ARTICLE
Janneke A Eken, Marvyn T Koning, Kristyna Kupcova, Julieta H Sepúlveda Yáñez, Ruben A L de Groen, Edwin Quinten, Jurriaan Janssen, Cornelis A M van Bergen, Joost S P Vermaat, Arjen Cleven, Marcelo A Navarrete, Bauke Ylstra, Daphne de Jong, Ondrej Havranek, Hassan Jumaa, Hendrik Veelken
Diffuse large B cell lymphoma of activated B cell type (ABC-DLBCL), a major cell-of-origin DLBCL subtype, is characterized by chronic active B cell receptor (BCR) signaling and NF-κB activation, which can be explained by activating mutations of the BCR signaling cascade in a minority of cases. We demonstrate that autonomous BCR signaling, akin to its essential pathogenetic role in chronic lymphocytic leukemia (CLL), can explain chronic active BCR signaling in ABC-DLBCL. 13 of 18 tested DLBCL-derived BCR, including 12 cases selected for expression of IgM, induced spontaneous calcium flux and increased phosphorylation of the BCR signaling cascade in murine triple knockout pre-B cells without antigenic stimulation or external BCR crosslinking...
May 6, 2024: Journal of Experimental Medicine
https://read.qxmd.com/read/38511425/transplant-versus-no-transplant-in-myelodysplastic-syndrome-and-acute-myeloid-leukemia-with-tp53-mutation-a-referral-center-experience
#31
JOURNAL ARTICLE
Kittika Poonsombudlert, Sarah Mott, Benda Miller, Prajwal Dhakal, Anthony Snow, Sarah Hornberg, Ratdanai Yodsuwan, Christopher Strouse, Hira Shaikh, Margarida Magalhaes-Silverman, Grerk Sutamtewagul
A remarkably high rate of post-transplant relapse in patients with TP53-mutated myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) calls to question the utility of allogeneic stem cell transplant (HSCT). We, therefore, performed a retrospective analysis to compare the outcomes between HSCT (N = 38) versus non-HSCT (N = 45) approaches. Patients in the HSCT cohort were younger (median age 63 vs. 72) while patients in the non-HSCT cohort more commonly had complex karyotype with chromosome 17 aberrancy and 5q deletion (p < ...
March 21, 2024: European Journal of Haematology
https://read.qxmd.com/read/38508880/long-term-follow-up-of-the-combination-of-ofatumumab-high-dose-methylprednisolone-and-lenalidomide-for-untreated-chronic-lymphocytic-leukemia-with-biomarker-analysis
#32
JOURNAL ARTICLE
Julio C Chavez, Ariel Grajales, Jose Sandoval-Sus, Elyce Turba, Lisa Nodzon, Angimar Uriepero-Palma, Mohammad Ammad-Ud-Din, Eva Sahakian, Rami Komrokji, Lubomir Sokol, Frederick L Locke, Bijal Shah, Jeffrey Lancet, Eduardo M Sotomayor, Mohamed A Kharfan-Dabaja, Celeste Bello, Javier Pinilla-Ibarz
BACKGROUND: Advancements in frontline therapy and chemotherapy-sparing treatments in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have altered the treatment algorithms of this disease. We present a frontline alternative for treatment- naïve (TN) CLL/SLL patients. METHODS: This was a single-center, phase 2 study of high-dose methylprednisolone (HDMP) and ofatumumab with lenalidomide and ofatumumab consolidative therapy for all comers with TN CLL/SLL...
February 13, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38507118/cllu1-as-an-emerging-biomarker-in-chronic-lymphoid-leukemia
#33
REVIEW
Chunmeng Rong, Chenhao Liang, Jinze Shen, Yuhua Zhang, Qurui Wang, Fang Yang, Yalu Chen, Yuqing Luo, Meier Gu, Panpan Gao, Yongming Xia, Shiwei Duan
CLLU1, a disease-specific gene associated with chronic lymphoid leukemia (CLL), is located on chromosome 12q22. Previous studies considered CLLU1 to be a non-coding RNA; however, recent research has discovered that its coding sequence region possesses the potential to encode a short peptide similar to interleukin-4. Remarkably, abnormally elevated expression of CLLU1 has only been detected in chronic lymphoid leukemia among all hematological cancers. High CLLU1 expression often indicates more malignant pathological features and an unfavorable prognosis for patients...
March 20, 2024: Human Cell
https://read.qxmd.com/read/38505596/the-potential-of-circhipk3-as-a-biomarker-in-chronic-myeloid-leukemia
#34
REVIEW
Eduardo Wandame Gomez, Laura Berti De Paula, Rafael Diogo Weimer, Alessandra Helena da Silva Hellwig, Grazielle Motta Rodrigues, Ana Paula Alegretti, Jarbas Rodrigues de Oliveira
Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by leukocytosis and left shift. The primary molecular alteration is the BCR::ABL1, chimeric oncoprotein with tyrosine kinase activity, responsible for the initial oncogenesis of the disease. Therapy of CML was revolutionized with the advent of tyrosine kinase inhibitors, but it is still not considered curative and may present resistance and serious adverse effects. Discoveries in CML inaugurated a new era in cancer treatment and despite all the advances, a new biomarker is needed to detect resistance and adverse effects...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38503518/-chinese-guideline-for-diagnosis-and-treatment-of-hairy-cell-leukemia-2023
#35
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
December 14, 2023: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://read.qxmd.com/read/38499049/efficacy-and-safety-of-cladribine-in-combination-with-busulfan-and-cyclophosphamide-as-an-intensive-conditioning-regimen-preceding-allogeneic-hematopoietic-stem-cell-transplantation-in-relapsed-or-refractory-acute-myeloid-leukemia
#36
JOURNAL ARTICLE
Fang Xiao, Huanxu Guo, Xueqian Yan, Meiying Qi, Jingyi Zhang
BACKGROUND: Cladribine, an analogue of deoxyadenosine, is used for therapy of hematological malignancies. Cladribine-containing regimen has been recommended as a rescue therapy for relapsed or refractory (R/R) acute myeloid leukemia (AML). Its combination with busulfan plus cyclophosphamide (BuCy), as an intensive conditioning regimen prior to allogeneic hematopoietic stem cell transplantation (allo-HSCT), requires more clinical evidence. This study aimed to explore the efficacy and safety of cladribine plus BuCy administered as an intensive conditioning regimen before allo-HSCT in R/R AML patients...
March 16, 2024: Transplant Immunology
https://read.qxmd.com/read/38497960/severe-sepsis-during-treatment-for-childhood-leukemia-and-sequelae-among-adult-survivors
#37
JOURNAL ARTICLE
Kathryn P Goggin, Lu Lu, Danielle E Lee, Carrie R Howell, Deokumar Srivastava, Tara M Brinkman, Gregory T Armstrong, Nickhill Bhakta, Leslie L Robison, Mathew J Ehrhardt, Melissa M Hudson, Kevin R Krull, Ching-Hon Pui, Jeffrey Rubnitz, Kirsten K Ness, Joshua Wolf
IMPORTANCE: Children undergoing treatment for leukemia are at increased risk of severe sepsis, a dysregulated immune response to infection leading to acute organ dysfunction. As cancer survivors, they face a high burden of long-term adverse effects. The association between sepsis during anticancer therapy and long-term organ dysfunction in adult survivors of childhood cancer has not been examined. OBJECTIVE: To determine whether severe sepsis during therapy for leukemia in childhood is associated with subsequent chronic health conditions in adult survivors...
March 4, 2024: JAMA Network Open
https://read.qxmd.com/read/38497150/imatinib-treatment-and-longitudinal-growth-in-pediatric-patients-with-chronic-myeloid-leukemia-influence-of-demographic-pharmacological-and-genetic-factors-in-the-german-cml-paed-cohort
#38
JOURNAL ARTICLE
Sophie Stiehler, Stephanie Sembill, Oliver Schleicher, Michaela Marx, Manfred Rauh, Manuela Krumbholz, Axel Karow, Meinolf Suttorp, Joachim Woelfle, Carlo Maj, Markus Metzler
In children and adolescents, impaired growth due to tyrosine kinase inhibitor therapy remains an insufficiently studied adverse effect. This study examines demographic, pharmacological, and genetic factors associated with impaired longitudinal growth in a uniform pediatric cohort treated with imatinib. We analyzed 94 pediatric patients with chronic myeloid leukemia (CML) diagnosed in the chronic phase and treated with imatinib for >12 months who participated in the Germany-wide CML-PAEDII study between February 2006 and February 2021...
March 14, 2024: Haematologica
https://read.qxmd.com/read/38495482/cfl1-is-implicated-in-chronic-myeloid-leukemia-response-during-imatinib-therapy
#39
JOURNAL ARTICLE
Xiufeng Yin, Xia Li, Hao Jiang, Xiangjie Lin, Zhixin Ma, Xiaochang Chen, Qibei Teng, Jin Zhang, Jie Jin
Cofilin (CFL1) is one critical member of the actin deploy family (ADF). Overexpression of CFL1 is associated with aggressive features and poor prognosis in malignancies. We evaluated the expression of CFL1 in patients with chronic myeloid leukemia in the chronic phase (CML-CP), acute myelocytic leukemia (AML) and healthy controls. The role of CFL1 in imatinib therapy was also investigated using cell line. We found that the expression of CFL1 was lower in CML patients than that in healthy controls, and was significantly upregulated after imatinib therapy (p<0...
2024: Journal of Cancer
https://read.qxmd.com/read/38494482/disrupting-pro-survival-and-inflammatory-pathways-with-dimethyl-fumarate-sensitizes-chronic-lymphocytic-leukemia-to-cell-death
#40
JOURNAL ARTICLE
Maria Elena Mantione, Miriam Meloni, Ilenia Sana, Jessica Bordini, Martina Del Nero, Michela Riba, Pamela Ranghetti, Eleonora Perotta, Paolo Ghia, Lydia Scarfò, Marta Muzio
Microenvironmental signals strongly influence chronic lymphocytic leukemia (CLL) cells through the activation of distinct membrane receptors, such as B-cell receptors, and inflammatory receptors, such as Toll-like receptors (TLRs). Inflammatory pathways downstream of these receptors lead to NF-κB activation, thus protecting leukemic cells from apoptosis. Dimethyl fumarate (DMF) is an anti-inflammatory and immunoregulatory drug used to treat patients with multiple sclerosis and psoriasis in which it blocks aberrant NF-κB pathways and impacts the NRF2 antioxidant circuit...
March 18, 2024: Cell Death & Disease
keyword
keyword
31210
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.